DIFLUCORTOLONE VALERATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H36F2O5
Molecular Weight	478.5685
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=HHJIUUAMYGBVSD-YTFFSALGSA-N

InChI=1S/C27H36F2O5/c1-5-6-7-23(33)34-14-21(31)24-15(2)10-17-18-12-20(28)19-11-16(30)8-9-26(19,4)27(18,29)22(32)13-25(17,24)3/h8-9,11,15,17-18,20,22,24,32H,5-7,10,12-14H2,1-4H3/t15-,17+,18+,20+,22+,24-,25+,26+,27+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C27H36F2O5
Molecular Weight	478.5685
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdf
Curator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332

Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Annexin A1 17 Target ID: P04083 Gene ID: 301.0 Gene Symbol: ANXA1 Target Organism: Homo sapiens (Human) Sources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdf	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute and chronic skin diseases 2 Sources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdf	Primary		Approved 8429	NERISONE Approved Use NERISONE® (diflucortolone valerate) preparations are indicated for the topical treatment of corticosteroid-responsive acute and chronic skin diseases, where anti-inflammatory, anti-allergic and anti-pruritic action is required for a maximum duration of 4 weeks.

PubMed

Title	Date	PubMed
[Clinical trial of diflucortolone. Preliminary report].	1981	7026942
Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model.	1998 Dec	9920209
Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature.	2014	25328491

Patents

Sample Use Guides

In Vivo Use Guide

Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.

Route of Administration: Topical

In Vitro Use Guide

In the vasoconstriction test on human skin, in which hyperemia has been experimentally induced, a water/oil emulsion with 0.001% diflucortolone valerate is as effective as a similar preparation containing 0.1% fluocortolone.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:14:29 GMT 2023` Edited by `admin` on `Fri Dec 15 19:14:29 GMT 2023`
Record UNII	1A63Z067C8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIFLUCORTOLONE VALERATE

Common Name

English

DIFLUCORTOLONE 21-VALERATE [MI]

Common Name

English

DIFLUCORTOLONE VALERATE [JAN]

Common Name

English

DIFLUCORTOLONE VALERATE [MART.]

Common Name

English

BAY-866146

Code

English

BAY866146

Code

English

Diflucortolone valerate [WHO-DD]

Common Name

English

DIFLUCORTOLONE 21-VALERATE

Common Name

English

Code System Code Type Description

EVMPD

SUB01694MIG